|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Thomas_J._Appio
|
|
gptkbp:country
|
gptkb:Canada
|
|
gptkbp:formerName
|
gptkb:Valeant_Pharmaceuticals_International
|
|
gptkbp:foundedYear
|
1959
|
|
gptkbp:headquartersLocation
|
gptkb:Laval,_Quebec,_Canada
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bausch Health
|
|
gptkbp:industry
|
healthcare
pharmaceuticals
|
|
gptkbp:ISIN
|
CA0717341071
|
|
gptkbp:legalForm
|
gptkb:public_company
|
|
gptkbp:market
|
gptkb:Canada
gptkb:United_States
International
|
|
gptkbp:marketCap
|
~$3.5 billion (2023)
|
|
gptkbp:netIncome
|
-$0.52 billion (2022)
|
|
gptkbp:notableEvent
|
involved in drug pricing controversies
subject of U.S. federal investigations
Valeant Pharmaceuticals rebranded as Bausch Health in 2018
|
|
gptkbp:notablePerson
|
gptkb:Joseph_C._Papa
gptkb:Thomas_J._Appio
gptkb:J._Michael_Pearson
|
|
gptkbp:notableProduct
|
gptkb:Solta_Medical
gptkb:Jublia
gptkb:Relistor
gptkb:Xifaxan
|
|
gptkbp:numberOfEmployees
|
~7000
|
|
gptkbp:products
|
medical devices
prescription drugs
over-the-counter products
|
|
gptkbp:revenue
|
$8.12 billion (2022)
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:BHC
|
|
gptkbp:subsidiary
|
gptkb:Solta_Medical
gptkb:Bausch_+_Lomb
gptkb:Salix_Pharmaceuticals
|
|
gptkbp:website
|
https://www.bauschhealth.com/
|
|
gptkbp:bfsParent
|
gptkb:Cuprimine
gptkb:Glumetza_XR
gptkb:Relistor
gptkb:Glumetza
|
|
gptkbp:bfsLayer
|
7
|